Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in the blood.
Label excerpts include indication to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia and adjunct to maximally tolerated statin therapy in adults with elevated TG levels (≥150 mg/dL).
Some antidepressants, especially SSRIs, can increase the risk of bleeding when combined with other medications that affect blood clotting, such as Vascepa.
Label supports increased bleeding risk with concomitant antithrombotic medications and advises monitoring for bleeding with concomitant anticoagulants/antiplatelet agents; however, antidepressants/SSRIs specifically are not mentioned in provided excerpts.
Combining SSRIs with Vascepa may increase the risk of bleeding.
Bleeding risk is increased with concomitant antithrombotic medications; antidepressants/SSRIs are not addressed in provided excerpts.
The bleeding risk from combining SSRIs with Vascepa may be higher in patients with a history of bleeding disorders.
Provided excerpts state bleeding incidence is greater in patients receiving concomitant antithrombotic medications; no label excerpt about bleeding history/bleeding disorders.
The bleeding risk from combining SSRIs with Vascepa may be higher in patients taking other medications that affect blood clotting.
Label: incidence of bleeding greater with concomitant antithrombotic medications (e.g., aspirin, clopidogrel, warfarin) and monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding.
Tricyclic antidepressants (TCAs) may interact with Vascepa by increasing the risk of bleeding.
Label supports bleeding risk with anticoagulants/antiplatelet agents; no label excerpt for TCAs.
Serotonin-norepinephrine reuptake inhibitors (SNRIs) may interact with Vascepa by increasing the risk of bleeding.
Label supports bleeding risk with anticoagulants/antiplatelet agents; no label excerpt for SNRIs.
Vascepa patents are owned by Icahn School of Medicine at Mount Sinai and Amarin Pharma.
Not supported or addressed in provided FDA label excerpts.
The patent for Vascepa is set to expire in 2025.
Not supported or addressed in provided FDA label excerpts.
It is expected that Amarin Pharma will continue to market Vascepa after the patent expires.
Not supported or addressed in provided FDA label excerpts.
Unsupported Statements
Vascepa works by inhibiting inflammation.
No mechanism of action statement in provided label excerpts mentions inhibiting inflammation.
Vascepa works by reducing triglyceride production in the liver.
Provided label excerpt for mechanism of action does not specifically state 'reducing triglyceride production in the liver'; it instead describes effects such as reducing hepatic VLDL-TG synthesis/secretion and/or enhancing TG clearance, and other mechanisms (DGAT inhibition, decreased lipogenesis).
Although rare, combining SSRIs with Vascepa may lead to serotonin syndrome.
No label excerpt provided mentions serotonin syndrome or interactions involving SSRIs.
Serotonin syndrome is a potentially life-threatening condition caused by excessive levels of serotonin in the body.
No such warning/definition appears in the provided FDA label excerpts.
Tricyclic antidepressants (TCAs) may interact with Vascepa by increasing the risk of serotonin syndrome.
No label excerpt provided mentions serotonin syndrome or TCA interactions with VASCEPA.
Serotonin-norepinephrine reuptake inhibitors (SNRIs) may interact with Vascepa by increasing the risk of serotonin syndrome.
No label excerpt provided mentions serotonin syndrome or SNRI interactions with VASCEPA.
Vascepa patents are owned by Icahn School of Medicine at Mount Sinai and Amarin Pharma.
Not supported in provided FDA label excerpts.
The patent for Vascepa is set to expire in 2025.
Not supported in provided FDA label excerpts.
It is expected that Amarin Pharma will continue to market Vascepa after the patent expires.
Not supported in provided FDA label excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Approved indication details were not fully stated (e.g., adjunct to maximally tolerated statin therapy to reduce risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization; and adjunct to diet for severe hypertriglyceridemia).
Importance:
Moderate
Dosage regimen (4 g/day as 0.5 g BID x4 capsules or 1 g BID x2 capsules) and administration instructions (swallow whole; do not break open/crush/dissolve/chew) were not provided.
Importance:
High
Contraindication for known hypersensitivity to VASCEPA or its components was omitted.
Importance:
High
Label drug interaction guidance provided in excerpts is specific to bleeding risk with anticoagulants and/or antiplatelet agents and advises monitoring for bleeding; the response instead focused on antidepressants (SSRIs/TCAs/SNRIs) without label support.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response includes unsupported interaction claims (serotonin syndrome with SSRIs/TCAs/SNRIs) and omits key label safety-critical elements (contraindication and precise dosing/administration). It partially aligns with label bleeding risk only in the general context of concomitant antithrombotics, but the antidepressant-specific assertions are not supported by provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Multiple statements are unsupported by the provided FDA label excerpts, especially serotonin syndrome and antidepressant-specific interaction claims; also key label elements (contraindication, dosing, administration) are omitted.
Suggested Improvement
Restrict safety and interaction statements to what the label excerpts support (bleeding risk with concomitant anticoagulants/antiplatelet agents and monitoring). Include the approved indications, the exact 4 g/day dosing with food, and the administration instruction to swallow capsules whole; add the contraindication for hypersensitivity. Remove or reframe serotonin syndrome/antidepressant-specific interaction claims unless present in the supplied label text.